Latest news and press releases about Coeptis Therapeutics Holdings, Inc. (COEP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Price
| Price | $10.99 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.50 |
| EV / EBITDA | -5.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -69.09% |
| Return on Invested Capital | -71.70% |
| Return on Assets | -60.06% |
| Gross Margin | 86.75% |
| Operating Margin | -956.94% |
| Net Margin | -874.29% |
Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX
Explore sector: Technology · Software - Services
More sections of COEP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks